Latanoprost Stadafarma

Latanoprost, the active ingredient in Latanoprost Stadafarma, is a Prostaglandin F2α analog presented as an ophthalmic solution for ocular use. It is employed to lower intra‑ocular pressure in patients with open‑angle glaucoma and ocular hypertension. GNH USA supplies Latanoprost Stadafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost belongs to the prostaglandin analog class used to manage ocular pressure‑related conditions. - Open‑angle glaucoma: reduces intra‑ocular pressure to prevent optic nerve damage. - Ocular hypertension: lowers eye pressure to decrease the risk of developing glaucoma. - Pre‑glaucoma ocular hypertension: maintains target pressure to delay progression to glaucoma.

Latanoprost may cause ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Eye irritation: transient burning or stinging sensation. - Increased eyelash growth: longer, thicker lashes. - Iris pigmentation: gradual darkening of eye color. - Blurred vision: temporary focus changes. - Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects: - Uveitis: inflammation of the uveal tract. - Corneal edema: swelling of the cornea affecting vision. - Severe allergic reaction: swelling, rash, or anaphylaxis. - Vision loss: sudden decrease in visual acuity. - Paradoxical IOP increase: unexpected rise in eye pressure. - Systemic hypersensitivity: fever, chills, or malaise.

Before prescribing Latanoprost, consider patient‑specific factors and monitor for adverse events. - Assess baseline intra‑ocular pressure: establish target pressure before therapy. - Monitor iris color changes: inform patients of possible permanent darkening. - Avoid use in active ocular infection: may exacerbate inflammation. - Counsel on eyelash growth: discuss cosmetic changes. - Discontinue if hypersensitivity occurs: stop treatment immediately. - Store at room temperature: keep in original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents, requiring careful management.

Major Interactions (Avoid): - Concurrent prostaglandin analogs: may cause excessive IOP reduction. - Systemic carbonic anhydrase inhibitors: increase risk of ocular side effects.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may diminish Latanoprost efficacy. - Other ocular hypotensive agents: monitor IOP for additive effects. - Contact lens wear: may increase irritation; advise removal before instillation.